NASDAQ: BIOSBioplus Acquisition Corp Stock
$10.41-0.01 (-0.1%)
Updated Mar 17, 2023
BIOS Price
$10.41
Fair Value Price
N/A
Market Cap
$305.12M
52 Week Low
$9.88
52 Week High
$10.43
P/E
N/A
P/B
-21.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.04
Operating Cash Flow
-$1M
Beta
-0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BIOS Overview
BioPlus Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or other similar business combinations. It targets companies in the life sciences industry. BioPlus is sponsored by BioPlus Sponsor LLC and Cantor Fitzgerald & Co. The company was incorporated in 2021 and is based in New York, NY.
Zen Score
–
Industry Average (6)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOS's cash and short-term investments ($107.07k) cannot cover BIOS's cash burn for the next year ($1.22M), once increasing cash burn (N/A) is accounted for
Interest Coverage Financials
BIOS's short-term assets ($628.56k) exceed its short-term liabilities ($288.45k)
Short-term Liabilities Financials
BIOS's long-term liabilities ($14.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more BIOS due diligence checks available for Premium users.
Be the first to know about important BIOS news, forecast changes, insider trades & much more!
BIOS News
Valuation
BIOS fair value
Fair Value of BIOS stock based on Discounted Cash Flow (DCF)
Price
$10.41
Fair Value
$10.40
Overvalued by
0.05%
BIOS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
17.79x
Market
21.81x
BIOS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-21.1x
Industry
-38.44x
BIOS's financial health
Profit margin
Revenue
$0.0
Net Income
$659.1k
Profit Margin
0%
BIOS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$236.5M
Liabilities
$15.1M
Debt to equity
-1.04
BIOS's short-term assets ($628.56k) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOS's long-term liabilities ($14.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$187.6k
Investing
$0.0
Financing
$0.0
BIOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOS vs Shell Company Stocks
Bioplus Acquisition Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.